- Elekta’s net sales for the second quarter were SEK4.34 billion, falling short of the estimated SEK4.51 billion.
- The operating profit was SEK388 million, compared with the estimated SEK440 million.
- Adjusted operating profit reached SEK423 million.
- The adjusted EPS was SEK0.63, below the expected SEK0.82.
- Ebitda was recorded at SEK706 million.
- The company expects an improvement in sales and profitability in the second half of the year due to new product launches and productivity measures.
- Net sales are forecasted to grow by mid-single digits for the full fiscal year 2024/25, alongside an improved EBIT margin.
- Beyond this fiscal year, Elekta aims for an EBIT margin of 14% or more, driven by strong customer interest and long-term demand for cancer care solutions.
- Sales decreased by 2% in constant exchange rates during the first half, compared to the same period last year.
- Measures are being implemented to further enhance profitability.
- Elekta has achieved its goal of reaching 300 million people in underserved markets.
- The current investment outlook for the company includes 6 buy ratings, 6 hold ratings, and 8 sell ratings.
A look at Elekta AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Elekta AB shows a positive long-term outlook. With a strong score of 4 in Dividend and Momentum, the company is positioned well for future growth and profitability. A score of 3 in both Value and Growth indicates stability and potential for increased value over time. The Resilience score of 3 reflects Elekta AB‘s ability to withstand market challenges and maintain its performance. Overall, Elekta AB‘s Smart Scores suggest a promising trajectory in the coming years.
Elekta AB, a company specializing in advanced medical products for the treatment of neurological disorders and cancer radiation, has a global reach with its innovative technologies. Notably, Elekta is known for pioneering the Gamma Knife, a cutting-edge tool for non-invasive surgery to treat intricate intracranial lesions. With a comprehensive system for stereotactic neurosurgery, Elekta is at the forefront of medical advancements, catering to a worldwide market. The company’s promising Smart Scores indicate a solid foundation for continued success in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
